Temasek co-leads $35m pre-Series B round in China's Lupeng Pharma

Temasek co-leads $35m pre-Series B round in China's Lupeng Pharma

Guangzhou-based Lupeng Pharmaceuticals, a clinical-stage firm that focuses on drug discovery and developing novel therapies for cancer, has snapped up $35 million in the second tranche of its pre-Series B round.

The round was led by Hangzhou-headquartered Kaitai Capital and Singapore state investor Temasek, Lupeng announced via its WeChat account.   

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief
Subscribe to Newsletter